期刊： HEALTH AFFAIRS, 2022; 41 (5)
Substantial controversy arose in 2021 when the Food and Drug Administration (FDA) approved the Alzheimer's disease drug aducanumab (Aduhelm) under its......
期刊： HEALTH AFFAIRS, 2022; 41 (7)
To understand the current state of prediabetes burden and treatment in the US, we examined recent trends in prediabetes prevalence, testing, and acces......
期刊： HEALTH AFFAIRS, 2022; 41 (10)
In the US population, the burden of disability among transgender adults compared with their cisgender peers is largely unknown. This study used seven ......
期刊： HEALTH AFFAIRS, 2022; 41 (1)
The US is experiencing a shortage of primary care providers, which could be reduced by the addition of nurse practitioners. However, the ability to in......
期刊： HEALTH AFFAIRS, 2022; 41 (3)
Medical-legal partnerships integrate legal advocates into health care settings to address health-related social needs. However, their effect on health......
期刊： HEALTH AFFAIRS, 2022; 41 (2)
Recent events have amplified the debilitating effects of systemic racism on the health of the United States. In an effort to improve population health......
期刊： HEALTH AFFAIRS, 2022; 41 (2)
Examining how spatial access to health care varies across geography is key to documenting structural inequalities in the United States. In this articl......
期刊： HEALTH AFFAIRS, 2022; 41 (3)
The Medicare Hospital Readmissions Reduction Program (HRRP) financially penalizes hospitals with high readmission rates. In fiscal year 2019 the progr......
